In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide

Kidney International

Volumn 76, Issue 4, 2009, Pages 437-444

  Vaziri, Nosratola D ^a   Moradi, Hamid ^a   Pahl, Madeleine V ^a   Fogelman, Alan M ^b   Navab, Mohamad ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti inflammatory agents; Atherosclerosis; Cardiovascular disease; Inflammation; Lipid disorders; Oxidative stress

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; IN VITRO STUDY; INCUBATION TIME; KIDNEY FAILURE; MALE; MONOCYTE; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS; APOLIPOPROTEIN A-I; CASE-CONTROL STUDIES; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION MEDIATORS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MOLECULAR MIMICRY; PEPTIDE FRAGMENTS; PLASMA;

EID: 68249123800     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.177     Document Type: Article

References (65)

1. Excerpts from the United States Renal Data system 2005 Annual Data Report. Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2006; 47: S1-S286.
2. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
3. Kovesdy CP, Trivedi BK, Anderson JE. Associations of kidney function with mortality in patients with chronic kidney disease not yet on dialysis: a historical prospective cohort study. Adv Chronic Kidney Dis 2006; 13: 183-188.
4. Muntner P, He J, Astor BC et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005; 16: 529-538.
5. Vaziri ND. Effect of chronic renal failure on nitric oxide metabolism. Am J Kidney Dis 2001; 38: S74-S79.
6. Vaziri ND. Oxidative stress in chronic renal failure: The nature, mechanism and consequences. Semin Nephrol 2004; 24: 469-473.
7. Vaziri ND, Ni Z, Wang XQ et al. Downregulation of nitric oxide synthase in chronic renal insufficiency: Role of excess PTH. Am J Physiol, Renal Physiol 1998; 274: F642-F649.
8. Himmelfarb J, Stenvinkel P, Ikizler TA et al. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-1538.
9. McCullough PA. Why is chronic kidney disease the 'spoiler' for cardiovascular outcomes? J Am Coll Cardiol 2003; 41: 725-728.
10. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: Sources, consequences, and therapy. Semin Dial 2002; 15: 329-337.
11. Vaziri ND. Dyslipidemia of chronic renal failure: The nature, mechanisms and potential consequences. Am J Physiol, Renal Physiol 2006; 290: 262-272.
12. Hansson GK, Robertson AK, Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol 2006; 1: 297-329.
13. Wilensky RL, Hamamdzic D. The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation. Curr Opin Cardiol 2007; 22: 545-551.
14. Shashkin P, Dragulev B, Ley K. Macrophage differentiation to foam cells. Curr Pharm Des 2005; 11: 3061-3072.
15. Obryshev YV. Monocyte recruitment and foam cell formation in atherosclerosis. Micron 2006; 37: 208-222.
16. Botham KM, Moore EH, De Pascale C et al. The induction of macrophage foam cell formation by chylomicron remnants. Biochem Soc Trans 2007; 35: 454-458.
17. Gleissner CA, Leitinger N, Ley K. Effects of native and modified low-density lipoproteins on monocyte recruitment in atherosclerosis. Hypertension 2007; 50: 276-283.
18. Davidson MH, Toth PP. High-density lipoprotein metabolism: potential therapeutic targets. Am J Cardio 2007; 100: n32-n40.
19. Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol 2003; 23: 1724-1731.
20. Navab M, Imes SS, Hama SY et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991; 88: 2039-2046.
21. Watson AD, Berliner JA, Hama SY et al. Protective effect of high density lipoprotein associated paraxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96: 2882-2891.
22. Ansell BJ, Navab M, Hama S et al. Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-denisty lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003; 108: 2751-2756.
23. Feig JE, Shamir R, Fisher EA. Atheroprotective effects of HDL: beyond reverse cholesterol transport. Curr Drug Targets 2008; 9: 196-203.
24. Yu R, Yekta B, Vakili L et al. Proatherogenic high-density lipoprotein, vascular inflammation, and mimetic peptides. Curr Atheroscler Rep 2008; 10: 171-176.
25. Haque S, Mirjafari H, Bruce IN. Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Curr Opin Lipidol 2008; 19: 338-343.
26. Ansell BJ, Fonarow GC, Fogelman AM. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol 2007; 18: 427-434.
27. Attman PO, Alaupovic P, Gustafson A. Serum apolipoprotein profile of patients with chronic renal failure. Kidney Int 1987; 32: 368-375.
28. Attman PO, Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia-relation to renal function and dialysis. Nephron 1991; 57: 401-410.
29. Muntner P, Hamm LL, Kusek JW et al. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004; 140: 9-17.
30. Kamanna VS, Kashyap ML, Pai R et al. Uremic serum subfraction inhibits apolipoprotein A-I production by a human hepatoma cell line. J Am Soc Nephrol 1994; 5: 193-200.
31. Shah GM, Lin ZL, Kamanna VS et al. Effect of serum subfractions from peritoneal dialysis patients on Hep-G2 cell apolipoprotein A-I and B metabolism. Kidney Int 1996; 50: 2079-2087.
32. Vaziri ND, Deng G, Liang K. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant 1999; 14: 1462-1466.
33. Moradi H, Pahl MV, Elahimehr R et al. Impaired Antioxidant Activity of HDL in Chronic Kidney Disease. Translational Res 2009; 153: 77-85.
34. Kalantar-Zadeh K, Kopple JD, Kamranpour N et al. HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int 2007; 72: 1149-1156.
35. Belalcazar LM, Merched A, Carr B et al. Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia. Circulation 2003; 107: 2726-2732.
36. Tangirala RK, Tsukamoto K, Chun SH et al. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 1999; 100: 816-822.
37. Calabresi L, Sirtori CR, Paoletti R et al. Recombinant apolipoprotein A-I Milano for the treatment of cardiovascular diseases. Curr Atheroscler Rep 2006; 8: 163-167.
38. Nissen SE, Tsunoda T, Tuzcu EM et al. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290: 2292-2300.
39. Navab M, Anantharamaiah GM, Hama S et al. D-4F and statins synergize to render HDL anti-inflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005; 25: 1426-1432.
40. Navab M, Anantharamaiah GM, Reddy ST et al. Oral D-4F causes formation of pre-b high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 2004; 109: 3215-3220.
41. Li X, Chyu KY, Faria Neto JR et al. Differential effects of apolipoprotein A-I mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 2004; 110: 1701-1705.
42. Shah PK, Chyu KY. Apolipoprotein A-I mimetic peptides: potential role in atherosclerosis management. Trends Cardiovasc Med 2005; 15: 291-296.
43. Ou J, Ou Z, Jones DW et al. L-4F, an apolipoprotein A-I mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 2003; 107: 2337-2341.
44. Ou J, Wang J, Xu H et al. Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet. Circ Res 2005; 97: 1190-1197.
45. Navab M, Anantharamaiah GM, Reddy ST et al. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med 2006; 3: 540-547.
46. Van Lenten BJ, Wagner AC, Nayak DP et al. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation 2001; 103: 2283-2288.
47. Charles-Schoeman C, Banquerigo ML, Hama S et al. Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis. Clin Immunol 2008; 127: 234-244.
48. Navab M, Anantharamaiah GM, Fogelman AM. The effect of apolipoprotein mimetic peptides in inflammatory disorders other than atherosclerosis. Trends Cardiovasc Med 2008; 18: 61-66.
49. Glomset JA. The plasma lecithins: cholesterol acyltransferase reaction. J Lipid Res 1968; 9: 155-167.
50. Vaziri ND, Liang K, Parks JS. Downregulation of hepatic lecithin: cholesterol acyltransferase (LCAT) gene expression in chronic renal failure. Kidney Int 2001; 59: 2192-2196.
51. Vaziri ND, Liang K. ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure. Am J Physiol Renal Physiol 2004; 287: F1038-F1043.
52. Bories PC, Subbaiah PV, Bagdade JD. Lecithin: cholesterol acyltransferase activity in dialyzed and undialyzed chronic uremic patients. Nephron 1982; 32: 22-27.
53. Guarnieri GF, Moracchiello M, Campanacci L et al. Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia. Kidney Int Suppl 1978; 8: S26-S30.
54. Boadu E, Bilbey NJ, Francis GA. Cellular cholesterol substrate pools for adenosine-triphosphate cassette transporter A1-dependent high-density lipoprotein formation. Curr Opin Lipidol 2008; 19: 270-276.
55. Bowry VW, Stanley KK, Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci USA 1992; 89: 10316-10320.
56. Deigner HP, Hermetter A. Oxidized phospholipids: emerging lipid mediators in pathophysiology. Curr Opin Lipidol 2008; 19: 289-294.
57. Mehta JL, Chen J, Hermonat PL et al. Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res 2006; 69: 36-45.
58. Cominacini L, Pasini AF, Garbin U et al. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. J Biol Chem 2000; 275: 12633-12638.
59. Cominacini L, Rigoni A, Pasini AF et al. The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. J Biol Chem 2001; 276: 13750-13755.
60. Navab M, Anantharamaiah GM, Reddy ST et al. Mechanisms of disease: proatherogenic HDL-an evolving field. Nat Clin Pract Endocrinol Metab 2006; 2: 504-511.
61. Vaziri ND, Liang K. Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int 1996; 50: 1928-1935.
62. Kaysen GA. Hyperlipidemia in chronic kidney disease. Int J Artif Organs 2007; 30: 987-992.
63. Moradi H, Yuan J, Ni Z et al. Reverse cholesterol transport pathway in experimental chronic kidney disease. Am J Nephrol 2009; 30: 147-154.
64. Van Lenten BJ, Wagner AC, Jung C-L et al. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res 2008; 49: 2302-2311.
65. Navab M, Hama SY, Cooke CJ et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000; 41: 1481-1494.